UBS Analysts Might've Found Another BioMarin Catalyst By: Benzinga via Benzinga August 21, 2015 at 09:41 AM EDT In a report published Friday, UBS analyst Andrew Peters maintained a Buy rating on BioMarin Pharmaceutical Inc (NASDAQ: BMRN), with a ... Read More >> Related Stocks: Biomarin Pharmaceuticals UBS Group Ag ADR